当前位置: X-MOL 学术Lancet Respir. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Durvalumab lengthens survival in patients with NSCLC
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2017-09-21 , DOI: 10.1016/s2213-2600(17)30353-3
Priya Venkatesan

Progression-free survival is usually poor (around 8 months) in patients with advanced non-small-cell lung cancer (NSCLC) who have received chemoradiotherapy, and little progress has been made in this field. However, an interim analysis of a phase 3 trial has shown that median progression-free survival significantly lengthened to more than 16 months after treatment with the anti-programmed death ligand-1 antibody durvalumab (compared with less than 6 months with placebo), in patients with stage III disease.

中文翻译:

Durvalumab延长了NSCLC患者的生存期

接受放化疗的晚期非小细胞肺癌(NSCLC)患者的无进展生存期通常较差(约8个月),在该领域进展甚微。然而,一项3期临床试验的中期分析显示,在接受抗编程死亡配体1抗体durvalumab治疗后,中位无进展生存期显着延长至16个月以上(与之相比,安慰剂治疗则少于6个月)。 III期疾病患者。
更新日期:2017-09-21
down
wechat
bug